Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael Bernard Mcandrew"'
Autor:
Nicholas Ian Workman, Pooja Agashe, Jens Koopmann, Lu Zou, Ezam Uddin, Andrew P. Cope, John Anson, Richard Stark, Michael Bernard Mcandrew, David L. Morris, Myles Lewis, Colin Wheeler, Timothy J. Vyse
Publikováno v:
Lewis, M J, McAndrew, M B, Wheeler, C, Workman, N, Agashe, P, Koopmann, J, Uddin, E, Morris, D L, Zou, L, Stark, R, Anson, J, Cope, A P & Vyse, T J 2018, ' Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus ', Journal of Autoimmunity . https://doi.org/10.1016/j.jaut.2018.02.009
Objectives The molecular targets of the vast majority of autoantibodies in systemic lupus erythematosus (SLE) are unknown. We set out to identify novel autoantibodies in SLE to improve diagnosis and identify subgroups of SLE individuals. Methods A ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9794edc64c5a0f3b674df4a8b9300371
https://kclpure.kcl.ac.uk/ws/files/89150748/Autoantibodies_targeting_TLR_and_LEWIS_SUPP_Publishedonline22March2018_GREEN_SUPP_AAM.pdf
https://kclpure.kcl.ac.uk/ws/files/89150748/Autoantibodies_targeting_TLR_and_LEWIS_SUPP_Publishedonline22March2018_GREEN_SUPP_AAM.pdf
Autor:
Myles Lewis, Colin Wheeler, Lu Zou, R. Stark, J. Anson, N. Workman, Timothy J. Vyse, Ezam Uddin, Michael Bernard Mcandrew, P. Agashe, J. Koopmann, Andrew P. Cope
Publikováno v:
Annals of the Rheumatic Diseases. 75:278.1-278
Background The molecular targets of the vast majority of autoantibodies in systemic lupus erythematosus (SLE) are unknown. Multiple recent failures of new therapies in SLE clinical trials demonstrate the need for improved classification of SLE based
Autor:
Ezam Uddin, Colin Wheeler, Timothy J. Vyse, Michael Bernard Mcandrew, Myles Lewis, J. Koopmann
Publikováno v:
Annals of the Rheumatic Diseases. 72:A760.2-A760
Background Accurate diagnosis of systemic lupus erythematosus (SLE) remains challenging. Despite many autoantibodies being identified, none of the currently available molecular tests including anti-dsDNA and anti-nuclear antibody (ANA), provides suff
Autor:
Michael Bernard Mcandrew, Pooja Agashe, Colin H. Wheeler, Nick Workman, John Anson, Ezam Uddin, Jens Koopmann
Publikováno v:
Cancer Research. 71:5071-5071
The issues surrounding the use of prostate-specific antigen (PSA) in the diagnosis of prostate cancer (PCa) are well documented and the need for a molecular diagnostic test with greater discriminatory power is clear. The development of autoantibodies